Noninvasive Localized Adipose Reduction With The Prostaglandin Analog Latanoprost
David T. Guerrero, MS, Matthew Cannon, PhD, Joseph Sukinik, BS, Phoebe Lee, BS, Sarah Seman, BS, Shawn J. Loder, MD, Anaya Shivakumar, BS, Solomon Su, PhD, Lauren Kokai, PhD.
University of Pittsburgh, Pittsburgh, PA, USA.
BACKGROUND: Unwanted focal adiposity in the face is a common patient complaint. While some indications are amenable to surgical intervention, not all patients want invasive procedures. Injectable alternatives are limited to deoxycholic acid (Kybella), a cytolytic FDA-approved drug for submental fat dissolution, though significant comorbid risks exist. In this study, we sought to determine if a prostaglandin analogue, Latanoprost, with known fat reducing iatrogenic effects can be safely used to diminish local fat in a mouse model.
METHODS: Human adipose obtained under IRB exemption was incubated for 14-days ex vivo with Kybella or variable Latanoprost concentrations. Mature adipocytes and the stromal vascular fractions were collected via enzymatic dissolution and size, count, morphology, and viability were assessed using Calcein-AM/PI imaging. Subsequently, single injections of Kybella and Latanoprost in mouse inguinal fat pads were investigated by measuring fat pad volume at 1 and 2 weeks after injection.
RESULTS: Incubation of lipoaspirate with Kybella resulted in total tissue dissolution and loss of viability. In contrast, latanoprost did not negatively affect viability of stromal cells or adipocytes. In vivo, both Kybella and Latanoprost reduced fat pad volume. H&E histology suggested Kybella was highly adipolytic and inflammatory while Latanoprost did not result in significant immunogenicity.
CONCLUSIONS: Single administration of soluble latanoprost safely reduced fat pad volume at two weeks post injection in vivo with no ex vivo loss of viability in human tissues. This supports a potential application for reduction in focal adiposity without undesirable cytologic injury. Additional mechanistic studies are underway.
Back to 2022 Abstracts